Registrieren

The Washington Post reported on promising results from a phase 3 trial of a personalized mRNA vaccine designed to prevent melanoma from returning after surgery. “This is exciting,” said Dr. Antoni Ribas, professor of medicine at the David Geffen School of Medicine at UCLA and director of the UCLA Health Jonsson Comprehensive Cancer Center’s tumor immunology and immunotherapy Program. “That hasn’t happened ever, with any cancer vaccine.” The treatment, which is tailored to mutations in an individual patient’s tumor and given alongside an existing immunotherapy, could eventually point toward new approaches for treating other cancers as well. Read more about UCLA in today’s Associated Press, New York Times and others.